Current status of hyperthermic limb perfusion for in-transit melanoma

References

• Grunhagan DJ, de Wilt JHW, van Geel AN, Eggermont AMM. Isolated limb perfusion for melanoma patients - A review of its indications and the role for tumour necrosis factor-alpha. Eur J Surg Oncol 2006; 32: 370–381
   Web of Science ®Google Scholar
• Pawlik TM, Ross MI, Johnson MM, Schacerer CW, McClain DM, Mansfield PF, Lee JE, Cormier JN, Gershenwald JE. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005; 12(8)587–596
   PubMed Web of Science ®Google Scholar
• Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622–3634
   PubMed Web of Science ®Google Scholar
• Balch CM, Buzaid AC, Soong SJ, Gershenwald JE, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Jr, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635–3648
   PubMed Web of Science ®Google Scholar
• Hill S, Thomas JM. Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg 1996; 83: 509–512
   PubMed Web of Science ®Google Scholar
• Rols MP, Bachaud JM, Giraud P, Chevreau C, Roche H, Teissie J. Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res 2000; 10: 468–474
   PubMed Web of Science ®Google Scholar
• Heller R, Jaroszeski MJ, Reintgen DS, Puleo CA, DeConti RE, Gilbert RA, Glass LF. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998; 83: 148–157
   PubMed Web of Science ®Google Scholar
• Hsueh EC, Nathanson L, Foshag LJ, Essner R, Nizze JA, Stern SL, Morton DLI. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer 1999; 85: 2160–2169
   PubMed Web of Science ®Google Scholar
• Seegenschmiedt MH, Keiholz L, Altendorf-Hofmann A, Urban A, Schell H, Hohenberger W, Sauer RI. Palliative radiotherapy for recurrent and metastatic malignant melanoma: Prognostic factors for tumor response and long-term outcome: A 20 year experience. Int J Radiat Oncol Biol Phys 1999; 44: 607–618
   PubMed Web of Science ®Google Scholar
• Cohen MH, Jessup JM, Felix EL, Weese JL, Herberman RB. Intralesional treatment of recurrent cutaneous malignant melanoma: A randomized prospective study of intralesional bacillus Calmette-Guerin versus intralesional dinitrocholorobenzene. Cancer 1978; 41: 2456–2463
   PubMed Web of Science ®Google Scholar
• Storm FK, Sparks FC, Morton DL. Treatment for melanoma of the lower extremity with intralesional injection of bacilli Calmette Guerin and hyperthermic perfusion. Surg Gynecol Obstet 1979; 149: 17–21
   PubMedGoogle Scholar
• Von Wussow P, Block B, Hartmann F, Deicher HI. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 1998; 61: 1071–1074
   Google Scholar
• Calabro A, Singletary SE, Carrasco CH, Legha SS. Intra-arterial infusion chemotherapy in regionally advanced malignant melanoma. J Surg Oncol 1990; 43: 239–244
   PubMed Web of Science ®Google Scholar
• Karakousis CP, Kontzoglou K, Driscoll DL. Tourniquet infusion chemotherapy for extremity in-transit lesions in malignant melanoma. Ann Surg Oncol 1997; 4: 506–510
   PubMed Web of Science ®Google Scholar
• Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Semin Surg Oncol 1998; 134: 238–247
   Google Scholar
• Thompson JF, Kam PC. Isolated limb infusion for melanoma: A simple but effective alternative to isolated limb perfusion. J Surg Oncol 2004; 88: 1–3
   PubMed Web of Science ®Google Scholar
• Jaques DP. Major amputation for advanced malignant melanoma. Surg Gynecol Obstet 1089; 169: 1–6
   Google Scholar
• Kapma MR, Vrouenraets BC, Nieweg OE, van Geel AN, Noorda EM, Eggermont AMM, Kroon BBR. Major amputation for intractable extremity melanoma after failure of isolated limb perfusion. Eur J Sur Oncol 2005; 31: 95–99
   PubMed Web of Science ®Google Scholar
• Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, Sussman JJ, Kraybill WG, Kane JM, 3rd, Alexander H, et al. Randomized multicenter trial of hyperthermic isolated perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. L. Clin Oncol 2006; 24(25)4196–4201
   Web of Science ®Google Scholar
• Creech O, Krementz ET, Ryan RF, Winblad JNI. Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616–632
   PubMed Web of Science ®Google Scholar
• Stehlin JS, Jr. Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet 1969; 129: 305–308
   PubMedGoogle Scholar
• Storm FK, Morton DL. Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg 1985; 150: 32–35
   PubMed Web of Science ®Google Scholar
• Takkenberg RB, Vrouenraets AN, Gee V, Nieweg OE, Noorda EM, Eggermont AMM, Kroon BBR. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients. J Surg Oncol 2005; 91: 107–111
   PubMed Web of Science ®Google Scholar
• Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992; 16: 227–233
   PubMed Web of Science ®Google Scholar
• Klaase JM, Kroon BB, van Geel AN, van Wijk J, Franklin HR, Eggermont AM, Hart AA. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg 1994; 178: 564–572
   PubMed Web of Science ®Google Scholar
• Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997; 132: 903–907
   PubMed Web of Science ®Google Scholar
• Lingam MK, Byrne DS, Aitchison T, MacKie RM, McKay AJ. A single centre's experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb. Eur J Cancer 1996; 32A(10)1668–1673
   PubMed Web of Science ®Google Scholar
• Di Filippo F, Anza M, Rossi CR, Cavaliere F, Botti C, Lise M, Garinei R, Giannarelli D, Vasselli S, Zupi G, Cavaliere R. The application of hyperthermia in regional chemotherapy. Sem Surg Oncol 1998; 14(3)215–223
   PubMedGoogle Scholar
• Klaase JM, Kroon BB, Eggermont AM, van Geel AN, Schraffordt Koops H, Oldhoff J, Liénard D, Lejeune FJ, Berkel R, Franklin HR, et al. A retrospective comparative study evaluating the results of mild hyperthermia versus controlled normothermic perfusion for recurrent melanoma of the extremities. Eur J Cancer 1995; 31A(1)58–63
   PubMed Web of Science ®Google Scholar
• Noorda EM, Vrouenraets BC, Nieweg OE, Klasse JM, van der Zee J, Kroo BBR. Long-term results of a double perfusion schedule using high dose hyperthemia and melphalan sequentially in extensive melanoma of the lower limb. Melanoma Res 2003; 13: 395–399
   PubMed Web of Science ®Google Scholar
• Klop WM, Vrouenraets BC, van Geel AN, Eggermont AM, Klaase JM, Nieweg OE, Kroon BB, et al. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg 1996; 192: 457–472
   Google Scholar
• Feldman AL, Alexander HR, Jr, Bartlett DL, Fraker DL, Libutti SK. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol 1999; 6: 562–567
   PubMed Web of Science ®Google Scholar
• Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52–60
   PubMed Web of Science ®Google Scholar
• Lienard D, Eggermont AM, Schraffordt Koops H, Kroon BB, Rosenkaimer F, Autier P, Lejeune FJ. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III: Results of a multicentre pilot study. Melanoma Res 1994; 4(Suppl.1)21–26
   PubMed Web of Science ®Google Scholar
• Vaglini M, Santinami M, Manzi R, Inglese MG, Santoro N, Persiani L, Belli F. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma): Dose-finding experience at the National Cancer Institute of Milan. Melanoma Res 1994; 4(Suppl.1)35–38
   PubMed Web of Science ®Google Scholar
• Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon-gamma: Results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996; 14: 479–489
   PubMed Web of Science ®Google Scholar
• Lienard D, Eggermont AM, Koops B, Kroon B, Towse G, Hiemstra S, Schmitz P, Clarke J, Steinmann G, Rosenkaimer F, Lejeune FJ. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: A multicentre randomized phase II study. Melanoma Res 1999; 9: 491–502
   PubMed Web of Science ®Google Scholar
• Fraker DL, Alexander HR, Ross M, et al. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphaln plus tumor necrosis factor (TNF-alpha) plus interferon-gamma (IFN). Ann Surg Oncol 2002; 2(Suppl. 9)S8
   Google Scholar
• Hays AJ, Neuhaus SJ, Clark MA, Thomas JM. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol 2007; 14(1)230–238
   PubMed Web of Science ®Google Scholar
• Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Göhl J, Eggermont AM, Di Filippo F, Krementz ET, Ruiter D, Lejeune FJ. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial. J Clin Oncol 1998; 16: 2906–2912
   PubMed Web of Science ®Google Scholar
• Hafstrom L, Rudenstam CM, Blomquist E, Ingvar C, Jönsson PE, Lagerlöf B, Lindholm C, Ringborg U, Westman G, Ostrop L. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 1991; 9: 2091–2094
   PubMed Web of Science ®Google Scholar
• Noorda EM, Takkenberg B, Vrouenraets BC, Nieweg OE, van Geel BN, Eggermont AM, Hart GA, Kroon BB. Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma. Ann Surg Oncol 2004; 11: 491–499
   PubMed Web of Science ®Google Scholar
• Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905–910
   PubMedGoogle Scholar
• Vrouenraets BC, Kroon BBR, Klaase JM, Nieweg OE, van Slooten GW, van Dongen JA. Severe acute regional toxicity after normothermic or ‘mild’ hyperthermic isolated limb perfusion with melphalan for melanoma. Melanoma Res 1995; 5: 425–431
   PubMed Web of Science ®Google Scholar
• Vrouenraets BC, Kroon BB, Ogilvie AC, van Geel AN, Nieweg OE, Swaak AJ, Eggermont AM. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 1999; 6: 405–412
   PubMed Web of Science ®Google Scholar
• Vrouenraets BC, Kroon BB, Klasse JM, Bonfrer JM, Nieweg OE, van Slooten GW, van Dongen JA. Value of laboratory tests in monitoring acute regional toxicity after isolated limb perfusion. Ann Surg Oncol 1997; 4(1)88–94
   PubMed Web of Science ®Google Scholar
• Vrouenraets BC, Eggermont AM, Klaase JM, van Geel BN, van Dongen JA, Kroon BB. Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs. Eur J Surg Oncol 1994; 20: 681–685
   PubMedGoogle Scholar
• Vrouenraets BC, In’t Veld GJ, Nieweg OE, van Slooten GW, van Dongen JA, Kroon BB. Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan. Eur J Surg Oncol 1999; 25: 503–508
   PubMed Web of Science ®Google Scholar
• Noorda EM, van Kreij RHJ, Vrouenraets BC, Nieweg OE, Muller M, Kroon BB, Aaronson NK. The health related quality of life in long-term survivors of melanoma treated with limb perfusion. Eur J Surg Oncol 2007; 33(6)776–782
   PubMed Web of Science ®Google Scholar
• Menon C, Ghartey A, Canter R, Feldman M, Fraker DL. Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin. Ann Surg 2006; 244(4)781–791
   PubMed Web of Science ®Google Scholar